Previous 10 | Next 10 |
home / stock / msclf / msclf news
- Advancements on the Company's evaluation of potential new disease indication Toronto, Ontario--(Newsfile Corp. - October 11, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Company "), a drug discovery company aimed at developing therapeutics that regenerate muscle as...
Toronto, Ontario--(Newsfile Corp. - October 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Company "), a drug discovery company aimed at developing therapeutics that regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, ...
Toronto, Ontario--(Newsfile Corp. - October 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Corporation "), is pleased to announce that its wholly owned subsidiary Amphotericin B Technologies Inc. ("AmpB Tech") and NW PharmaTech Ltd. ("NWPT") have today established a ...
Toronto, Ontario--(Newsfile Corp. - October 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) (" Satellos " or the " Corporation "), a drug discovery company aimed at developing therapeutics that regenerate muscle as a new approach to treating disease conditions from muscular d...
Toronto, Ontario--(Newsfile Corp. - September 28, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Company "), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that its bo...
Toronto, Ontario--(Newsfile Corp. - July 25, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Corporation "), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Co-foun...
Toronto, Ontario--(Newsfile Corp. - July 13, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Corporation "), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Co-foun...
NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with Zacks Small-Cap Research, today announced the agenda for the upcoming Life Sciences Investor Forum to be held on June 23 rd . Individual inve...
NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with Zacks Small-Cap Research, today announced the agenda for the upcoming Life Sciences Investor Forum to be held on June 23 rd . Individual inve...
NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the March 10 th Life Sciences Investor Forum are now available for on-demand viewing. REGISTER OR LOGIN NOW ...
News, Short Squeeze, Breakout and More Instantly...
– Investigational New Drug (IND) enabling preclinical and toxicology studies successfully completed – Initiation of a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience Inc. (“Satellos” or the “Company”) ...
–SAT-3247 treatment improved muscle repair and regeneration in canine model of DMD – SAT-3247 treatment also improved muscle force in this canine model of DMD – Satellos remains on track to initiate a Phase 1 clinical trial in Q3 2024 Satellos Bios...
– Frank Gleeson, Satellos CEO, to participate in a panel discussion titled "Research Row: PPMD Moving the Needle" on June 29, 2024 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company d...